Use of Topical Clascoterone for the Treatment of Hidradenitis Suppurativa
April 2023
in “
JAAD Case Reports
”
Studysummary This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jaadcasereports.org →